Mazdutide vs Retatrutide (2026): Pipeline GLP-1 Drugs Compared
Mazdutide (mazdutide (IBI362 / LY3305677), Innovent Biologics / Eli Lilly) vs Retatrutide (retatrutide (LY3437943), Eli Lilly)
Last verified November 2026
The verdict
Mazdutide and retatrutide are both investigational in the United States, and all comparisons are cross-trial only, as no head-to-head study between them exists. Mazdutide (Innovent Biologics, under license from Eli Lilly) is a GLP-1/glucagon dual agonist that Innovent reports is approved in China for obesity and type 2 diabetes, the first approved drug of its class; its phase 3 trials ran mainly in Chinese adults, with GLORY-1 (NEJM 2025) showing −12.55% body weight at 32 weeks on 6 mg and GLORY-2 (JAMA 2026) evaluating a 9 mg dose. Our mazdutide explainer covers the China approval. Retatrutide (Eli Lilly) adds GIP receptor agonism to form a triple agonist and achieved −24.2% weight loss in its phase 2 trial (NEJM 2023, 12 mg, 48 weeks), and its phase 3 TRIUMPH-1 trial (NEJM 2026) reported −25.0% at 80 weeks on 12 mg versus −3.9% on placebo; the most-cited retatrutide studies collect the rest. The larger weight-loss figures for retatrutide cannot be used to declare a clinical winner because the trials used different populations (global vs. predominantly Chinese), dose escalation schedules, durations, and endpoints. Neither drug has liver-disease-specific published phase 3 data comparable to survodutide's program, set out in the Survodutide vs Retatrutide verdict. Patients should not expect access to either drug outside of clinical trials in the US.
Side-by-side comparison
| Field | Mazdutide | Retatrutide |
|---|---|---|
| Mechanism | GLP-1 / glucagon dual receptor agonist (GLP-1R + GcgR) | GLP-1 / GIP / glucagon triple receptor agonist (GLP-1R + GIPR + GcgR) |
| Phase 2 peak weight loss | −11.3% at 24 wk (6 mg; PMID 38092790, Nature Communications 2023) — cross-trial, 24-wk endpoint vs retatrutide's 48-wk endpoint; not directly comparable | −24.2% at 48 wk (12 mg; PMID 37366315, NEJM 2023) — cross-trial, not directly comparable to mazdutide figure |
| Phase 3 weight-loss data | GLORY-1 (PMID 40421736, NEJM 2025): −12.55% at 32 wk (6 mg) in Chinese adults; GLORY-2 (PMID 42251595, JAMA 2026): 9 mg dose evaluated in Chinese adults | TRIUMPH-1 (PMID 42814954, NEJM 2026): −23.7% (9 mg) and −25.0% (12 mg) at 80 wk vs −3.9% placebo |
| Trial stage / status | Phase 3 complete (GLORY-1 2025, GLORY-2 2026); conducted primarily in China; US regulatory status: investigational | Phase 3 TRIUMPH-1 and TRIUMPH-2 published 2026; US Biologics License Application submission planned Q1 2027 |
| Geographic scope / regulatory status | Approved in China for obesity and type 2 diabetes (per Innovent); not FDA-approved for the US market | Global phase-3 program; not FDA-approved |
| MASH / liver-disease evidence | No dedicated MASH or liver-disease clinical trial published | No dedicated MASH or liver-disease clinical trial published |
| Administration | Once-weekly subcutaneous injection | Once-weekly subcutaneous injection |
| FDA approval status | Not FDA-approved; investigational (US) | Not FDA-approved; investigational (US) |
Frequently asked questions
Is retatrutide or mazdutide more effective for weight loss?
No direct comparison exists. Retatrutide's phase-2 trial (NEJM 2023) reported −24.2% body weight loss at 48 weeks (12 mg), while mazdutide's GLORY-1 phase-3 trial (NEJM 2025) in Chinese adults showed −12.55% at 32 weeks (6 mg). These numbers come from trials with different designs, populations, durations, and dose levels — they cannot be used to rank one drug over the other without a head-to-head study.
How does mazdutide's dual mechanism compare to retatrutide's triple mechanism?
Mazdutide activates two receptors: GLP-1R (appetite suppression, insulin secretion) and GcgR (energy expenditure, liver fat). Retatrutide adds a third: GIPR (glucose-dependent insulin potentiation, adipose tissue signaling). Whether the added GIP agonism translates into meaningfully greater weight loss or metabolic benefit in practice is not established from cross-trial data, and no head-to-head study between these two drugs has been published.
Why are mazdutide's trials conducted mainly in China?
Mazdutide was developed primarily by Innovent Biologics, a Chinese biopharmaceutical company, in partnership with Eli Lilly. The GLORY-1 and GLORY-2 phase-3 trials enrolled Chinese adults with obesity. This means the evidence base reflects a Chinese population and body-composition context, and the results may not generalize directly to Western populations. Innovent reports the drug is approved in China for obesity and type 2 diabetes; it is not FDA-approved.
Is mazdutide approved anywhere in the world?
Yes, in China. China approved mazdutide for weight management in June 2025 and for type 2 diabetes in September 2025; Innovent's August 2026 interim report describes it as the first and only approved GLP-1/glucagon dual agonist for both, based on China-based phase 3 trials such as GLORY-1 (NEJM 2025) and GLORY-2 (JAMA 2026). It is not FDA-approved in the United States and is not commercially available in Western markets.
When could retatrutide or mazdutide be available in the US?
Neither is FDA-approved in the US as of October 2026; outside clinical trials, the only US route is a narrow physician-requested expanded access program for retatrutide (NCT07629401). Retatrutide's TRIUMPH-1 and TRIUMPH-2 phase-3 trials are published, and Eli Lilly plans to submit a Biologics License Application to the FDA in the first quarter of 2027. Mazdutide's phase-3 evidence is from China-based trials; a US/global development program would require additional regulatory engagement. Timelines for FDA review for either drug have not been publicly confirmed.
Do mazdutide and retatrutide share any connection to Eli Lilly?
Yes — both drugs have an Eli Lilly connection. Mazdutide (IBI362 / LY3305677) was co-developed with Innovent Biologics under a license from Lilly. Retatrutide (LY3437943) is a wholly Lilly-developed asset. They are distinct molecular entities in separate development programs and are not interchangeable.
References
- 1.Jastreboff AM, Karol A, Stefanski A, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial New England Journal of Medicine. 2023. PMID: 37366315.
- 2.Ji L, Jiang H, Cheng Z, et al. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity Nature Communications. 2023. PMID: 38092790.
- 3.Ji L, Jiang H, Bi Y, et al. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight New England Journal of Medicine. 2025. PMID: 40421736.
- 4.Gao L, Jiang H, Cai H, et al. Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial JAMA. 2026. PMID: 42251595.
- 5.Gadde KM, Talebloo J, Heymsfield SB, et al. Mazdutide and Orforglipron — New Evidence in Obesity and Diabetes JAMA. 2026. PMID: 42251768.
- 6.Ji L, et al. Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m² but without diabetes Med (New York). 2026. PMID: 41875890.
- 7.Jastreboff AM, Kaplan LM, Davies MJ, et al.; TRIUMPH-1 Investigators Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity N Engl J Med. 2026. PMID: 42814954.
- 8.Eli Lilly and Company Lilly reports second-quarter 2026 financial results (Form 8-K exhibit) U.S. Securities and Exchange Commission. 2026. https://www.sec.gov/Archives/edgar/data/0000059478/000005947826000077/q226lillysalesandearningsp.htm
- 9.Innovent Biologics Innovent Announces 2026 Interim Results and Business Updates PR Newswire. 2026. https://www.prnewswire.com/news-releases/innovent-announces-2026-interim-results-and-business-updates-302859305.html
Related comparisons
- Wegovy vs Zepbound
- Ozempic vs Mounjaro
- Semaglutide vs Tirzepatide
- Rybelsus vs Ozempic
- Mounjaro vs Zepbound
- Foundayo vs Rybelsus
See the full drug-vs-drug verdict index or provider rankings.